RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target

Area of Science:

• Virology
• Drug Discovery
• Medicinal Chemistry

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, necessitates effective therapeutic interventions.
• Viral RNA-dependent RNA polymerase (RdRp) is crucial for coronavirus replication and transcription.
• RdRp is a highly conserved enzyme across different coronaviruses, making it a promising broad-spectrum antiviral target.

Purpose of the Study:

• To review the antiviral potential of RdRp inhibitors, particularly nucleoside analogs.
• To provide a comprehensive overview of drug discovery efforts targeting SARS-CoV-2 RdRp.

Main Methods:

• Literature review of existing research on RdRp inhibitors.
• Analysis of the conserved nature of RdRp across SARS-CoV-2, SARS-CoV, and MERS-CoV.
• Focus on nucleoside analogs as a primary class of RdRp inhibitors.

Main Results:

• RdRp is a validated target for antiviral drug development against SARS-CoV-2.
• Nucleoside analogs demonstrate significant potential as SARS-CoV-2 RdRp inhibitors.
• The conserved structure of RdRp suggests potential for broad-spectrum coronavirus therapeutics.

Conclusions:

• Targeting the conserved RdRp enzyme is a viable strategy for developing novel antiviral therapies.
• Further research into RdRp inhibitors, especially nucleoside analogs, is crucial for combating SARS-CoV-2 and future coronavirus outbreaks.